Introduction
BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%-50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP).
1-6 Over 100 BCR-ABL1 single-point mutations have been reported in patients with imatinib-resistant CML, which confer different levels of TKI resistance. 7 A threonine to isoleucine substitution at the 315 residue (T315I), which forms a key H-bond interaction with TKIs, results in clinical insensitivity to imatinib, nilotinib, and dasatinib. 3, [8] [9] [10] [11] [12] [13] Other mutations, however, can be inhibited at least to some extent by second generation TKIs (SG-TKIs). The sensitivity of single-point mutations to nilotinib and dasatinib has been determined both in vitro and may inform the selection of TKI upon imatinib failure. 14 Patients with CML can acquire more than one BCR-ABL1 mutation during sequential TKI therapy, which may result in increased oncogenicity compared with each individual mutation. 15 We analyzed the response rates and survival of patients carrying more than one BCR-ABL1 mutation during sequential TKI therapy.
Design and Methods

Among 293 patients treated at MD Anderson Cancer Center
with SG-TKI after imatinib failure between (November 6, 2003) and (December 21, 2008) , mutation analysis was available in 207 (71%) (102 in CP, 61 in AP, and 44 in BP)( Table 1) . The complete kinase domain of the BCR-ABL1 oncogene was analyzed using seminested reverse transcriptase PCR followed by direct sequencing. 16 The study was conducted in compliance with the M.D.
Anderson Cancer Center Institutional Review Board.
Results and Discussion
The complete cytogenetic response (CCyR) rate with imatinib among patients in CP, AP, or BP was 35%, 19%, and 30%, respectively.BCR-ABL1 mutations upon imatinib failure were detected in 92 (44%) patients: 45% in CP, 54% in AP, and 30% in BP. Median time from diagnosis to detection of one mutation in CP, AP, and BP was 76 (range, 67 (range, , and 39 months (range, 3-189), respectively. Median time on imatinib for patients with one mutation in CP, AP, and BP was 51 (range, 14-80), 38 (range, 2-63), and 34 months (range, 2-56), respectively.
Median time from diagnosis to detection of more than one mutation in CP, AP, and BP was 81 (range, 23-126), 37 (range, 14-60) bosutinib: E255K/V, F317L, V299L, F486S)( Figure 1A -B). These data suggest that acquiring more than one mutation portends a poor prognosis similar to that associated with the acquisition of a single-point mutation highly resistant to SG-TKIs. Teleologically, the association with a second mutation would allow M351T, a mutation highly sensitive to SG-TKIs, to induce a fully TKI resistant phenotype. showed that among 61 patients with imatinib-resistant CML-CP, 57% of them harbored more than one BCR-ABL1 kinase domain mutation and that the latter were prone to cluster within the same leukemic clone. 21 However, the clinical impact of these clones representing a small proportion of the overall leukemic population remains unknown.
In conclusion, patients with CML-CP carrying more than one BCR-ABL1 kinase domain mutation exhibit worse response rates and long-term outcomes with TKI therapy compared with those with no or only one BCR-ABL1 mutation. A longer follow-up of a larger series of patients is warranted to confirm these intriguing observations. Table 1 . Response to tyrosine kinase inhibitor therapy of patients with more than one BCR-ABL1 mutation. Of note, in 5 of 6 evaluable patients (patients 2, 3, 4, 5, 6, and 7), therapy with second generation TKI (2 nd TKI) resulted in the elimination of one of the mutations present after imatinib failure. In 4 of those 5 cases (3, 4, 5, and 6) the remaining mutation was the one with the highest IC50 for the TKI used in each patient, suggesting that resistance and therefore a poor prognosis in patients with more than one mutation maybe primarily driven by the presence of a less sensitive mutation to 2 nd generation TKI. 0  28  9  3  3  5  6  2  32  15  54  20  71   1  31  10  0  3  3  13  2  32  13  42  16  52   2  2  1  0  0  0  1  0  50  1  50  1  50   Total  61  20  3  6  8  20  4  33  29  48  37  61 Suppl. Figure 1 . Event-free survival and overall survival for the whole cohort of patients (A) and for patients with CML-CP (B).
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